OWN - NLM
DA - 20170517
LR - 20170517
IS - 0042-4668 (Print)
IS - 0042-4668 (Linking)
VI - 82
IP - 2
DP - 2017
TI - [The role of topical glucocorticoids in the treatment of rhinosinusitis].
PG - 70-73
LID - 10.17116/otorino201782270-73 [doi]
AB - The guidelines of the European position paper on rhinosinusitis and nasal polyps
(EPOS, 2012) ascribe the highest strength and the most comprehensive
evidence-based significance to the application of intranasal glucocorticosteroids
(inGCS) as the first-line therapy for the patients presenting with acute and
polypous rhinosinusitis; moreover they are recommended as the medications of
choice for the treatment of chronic rhinosinusitis in the absence of polyps. The
author presents the data concerning the mechanism of action, clinical
effectiveness, and safety of inGCS used for the treatment of acute, recurrent,
and chronic rhinosinusitis. It is shown that mometason furoate produces the
favourable therapeutic effect and is possessed of beneficial pharmacodynamic and
pharmacokinetic properties in the cases of its topical application. The
comparative randomized clinical study (RCS) of the new preparation of mometason
furoate in the form of the intranasal spray (manufactured by 'Teva' Ltd.)
registered in the Russian Federation in 2015 has demonstrated that it can be
considered as a therapeutic equivalent to nasonex.
FAU - Shakhova, E G
AU - Shakhova EG
AD - Volgograd State Medical University, Ministry of Health of the Russian Federation,
Volgograd, Russian Federation.
LA - rus
PT - English Abstract
PT - Journal Article
TT - Mesto topicheskikh gliukokortikosteroidov v lechenii rinosinusita.
PL - Russia (Federation)
TA - Vestn Otorinolaringol
JT - Vestnik otorinolaringologii
JID - 0416577
CRDT- 2017/05/18 06:00
PST - ppublish
SO - Vestn Otorinolaringol. 2017;82(2):70-73. doi: 10.17116/otorino201782270-73.